Trial Profile
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Camicinal (Primary) ; Metoclopramide
- Indications Gastroparesis
- Focus Therapeutic Use
- Acronyms The NUTRIATE Study
- Sponsors GlaxoSmithKline; GSK
- 09 Oct 2017 Status changed from completed to discontinued.
- 23 Nov 2016 Status changed from recruiting to completed.
- 10 Nov 2015 Planned End Date changed from 1 Sep 2015 to 1 Aug 2016 as reported by Clinicaltrials.gov record.